All Posts Tagged With: "MNKD"
(BOBE) Company News for May 11, 2011 – Corporate Summary
• Microsoft Corp. (NASDAQ:MSFT) will purchase internet communications leader Skype from the investor consortium led by Silver Lake. The deal which is worth $8.5 billion in cash has been approved by the boards of directors of both companies • Dean Foods (NYSE:DF)...
11May2011 | vitalstocks | 0 comments | Continued(MNKD) MannKind Corporation’s Afrezza Drug Gets Good News
There was some good news for MannKind Corporation’s (MNKD) lead pipeline candidate, Afrezza, when the US Food and Drug Administration (FDA) rescheduled its end-of-review meeting with the company to discuss the candidate. A few days ago, the FDA cancelled the meeting, originally...
13Apr2011 | vitalstocks | 0 comments | Continued(MNKD) Why Phase II is the Sweet Spot for Biotech Investing
by Marc Lichtenfeld, Investment U’s Healthcare Expert Wednesday, April 13, 2011: Issue #1490 I recently received a call from an investor relations representative who wanted to know if I’d be interested in hearing about a small biotech company with a drug candidate in Phase...
13Apr2011 | InvestmentU | 0 comments | Continued(JNJ) Pharmaceutical Industry Outlook – March 2011 – Industry Outlook
The pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance...
2Mar2011 | vitalstocks | 0 comments | Continued(MNKD) MannKind Fourth Quarter Reports Smaller-than-Anticipated Loss
MannKind Corporation’s (MNKD) fourth quarter 2010 net loss of $0.33 per share was narrower than the Zacks Consensus Estimate of a loss of $0.40. The company had suffered a loss of $0.41 (excluding the loss of $12.8 million pertaining to the disposal of fixed assets) in the...
14Feb2011 | vitalstocks | 0 comments | Continued(AKS) Stock Market News for December 29, 2010 – Market News
After-effects from the blizzard which had hit the northeast continued as trading volumes remained thin for the second consecutive day and markets closed mixed on Tuesday. Oil prices and energy stocks, nonetheless, moved up primarily due to the blizzard. The Dow Jones Industrial...
29Dec2010 | vitalstocks | 0 comments | Continued(MNKD) MannKind Corporation Analyst Maintains Neutral Rating on Stock
We are maintaining our Neutral recommendation on MannKind Corporation (MNKD) with a target price of $6.25. MannKind is a Valencia, California-based biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diabetes, cancer...
11Sep2010 | vitalstocks | 0 comments | Continued(MNKD) MannKind Gets Good News From FDA
MannKind Corporation (MNKD) received a boost when the US Food and Drug Administration (FDA) accepted MannKind’s response to the complete response letter (CRL) issued by the agency on its inhaled insulin candidate, Afrezza. The candidate is being developed for treating type...
24Jul2010 | vitalstocks | 0 comments | Continued(ABT) Pharma & Biotech Stock Review – April 2010 – Industry Outlook
The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant...
29Apr2010 | vitalstocks | 0 comments | Continued(MNKD) MannKind Suffers Setback From FDA
MannKind Corp. (MNKD) suffered a major setback with respect to its lead product, Afrezza, inhaled insulin for treating type I and type II diabetes. The company received a complete response letter (CRL) from the US Food & Drug Administration (FDA) recently. The FDA has asked...
16Mar2010 | vitalstocks | 0 comments | Continued(MNKD) MannKind Narrows Fourth Quarter Loss
During the fourth quarter of 2009, MannKind (MNKD) lowered its loss per share to 53 cents compared to a loss of 82 cents in the year-ago period. However, the loss per share missed the Zacks Consensus Estimate of 41 cents. For the full year, MannKind reported a loss per share...
2Feb2010 | vitalstocks | 0 comments | Continued(DNDN) These Biotech Stocks Are Just What the Doctor Ordered
by Louise Harris, Investment U Research Thursday, January 28, 2010 They say that one in every nine women will get breast cancer. It’s a staggering statistic, just like the equally frightening claim that one in four people will end up with some type of cancer in their lifetimes…...
29Jan2010 | InvestmentU | 0 comments | Continued(RX) Pharma & Biotech Stock Review – Industry Outlook
The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant...
29Jan2010 | vitalstocks | 0 comments | Continued(MNKD) MannKind Corporation Gets FDA Setback
Recently, MannKind Corporation (MNKD) received a setback regarding the approval of its much awaited product Afrezza (formerly known as Afresa) ? inhaled insulin for the treatment of type I and type II diabetes. While the original Prescription Drug User Fee Act (PDUFA) date was...
11Jan2010 | vitalstocks | 0 comments | Continued(MNKD) MannKind Awaits US Food and Drug Administration Decision
The next few days will be very crucial for MannKind (MNKD). The US Food and Drug Administration (FDA) is expected to decide on the company’s lead product candidate Afresa, which is an inhaled insulin for the treatment of type I and type II diabetes, within January 16, 2010. We...
6Jan2010 | vitalstocks | 0 comments | Continued(RX) Big Pharma and Biotech – Industry Outlook
The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between...
9Nov2009 | Shawn | 0 comments | Continued(MNKD) MannKind Pharma Beats – Awaiting FDA Review
MannKind Pharma’s (MNKD) third quarter loss per share came in at 42 cents, better than the Zacks Consensus Estimate of 49 cents and loss of 67 cents reported in the year-ago period. The company does not have any revenue stream at present — its lead product, Afresa (inhaled...
4Nov2009 | vitalstocks | 0 comments | Continued